Last reviewed: July 12, 2026
Last updated: July 12, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has reshaped weight loss treatment by delivering measurable results for patients struggling with obesity and metabolic dysfunction. Clinical trials show that tirzepatide users achieve meaningful weight reduction when combined with lifestyle modification, making it one of the most effective injectable medications available today.
What the Clinical Data Shows About Tirzepatide Effectiveness
The SURMOUNT clinical trial series demonstrated that tirzepatide produces dose-dependent weight loss ranging from 15% to 22% of body weight over 72 weeks of treatment. Participants across different age groups and metabolic backgrounds achieved sustained reduction in both total body weight and visceral fat accumulation. These results represent a meaningful shift in obesity management, particularly for individuals who have not responded adequately to diet and exercise alone.
Beyond weight reduction, tirzepatide users show improvements in metabolic markers including fasting glucose, insulin resistance, and cardiovascular risk factors. The medication works by activating two hormone pathways simultaneously—the GLP-1 receptor pathway that controls appetite signaling, and the GIP receptor pathway that modulates glucose metabolism and energy expenditure. This dual mechanism explains why tirzepatide consistently outperforms single-pathway GLP-1 medications in head-to-head comparisons.
How Individual Genetics Influence Your Tirzepatide Response
The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
The FTO rs9939609 variant, associated with genetic predisposition to weight gain and hunger signaling dysregulation, can inform whether your tirzepatide dosing strategy should emphasize appetite suppression or metabolic activation. By understanding your unique genetic profile before starting treatment, PlexusDx users make more informed decisions about medication selection and expected timelines for seeing results. The Precision Peptide Genetic Test is available as a $99 add-on after your first month of treatment.
Real-World Success Rates: What to Expect in Your First Year
Most tirzepatide users begin experiencing appetite reduction within the first two weeks of treatment, with noticeable weight loss emerging between weeks 3 and 8. By month three, patients typically report 5% to 10% body weight reduction, and by month six, many reach 12% to 18% reductions. These timelines assume consistent adherence to the injection schedule, concurrent lifestyle modifications, and stable medical conditions—variables that significantly influence individual outcomes.
Success rates increase when tirzepatide is paired with structured nutrition guidance and regular physical activity. PlexusDx patients who engage in these supporting behaviors report higher satisfaction and sustainable weight maintenance compared to medication-only approaches. Your response may accelerate or plateau depending on starting weight, age, metabolic rate, and whether you have type 2 diabetes or prediabetes—all factors your PlexusDx provider considers during personalized treatment planning.
Tirzepatide vs. Other GLP-1 Options: Why Dual-Receptor Action Matters
Single-pathway GLP-1 receptor agonists like semaglutide produce weight loss primarily through appetite suppression and delayed gastric emptying, while tirzepatide's GIP co-agonism adds a metabolic-activation component that independently increases energy expenditure. Clinical comparisons show tirzepatide produces 2% to 6% greater weight reduction than equivalent-strength GLP-1-only medications, and this advantage persists across 12-month follow-up periods. PlexusDx offers both Compounded Tirzepatide Injection (starting at $289/mo (or $249/mo on the 6-month plan)) and Compounded Semaglutide Injection (starting at $189/mo (or $149/mo on the 6-month plan)), allowing you to select based on clinical fit and budget.
For patients seeking maximum potency, PlexusDx also offers GLP-Squared Injection—a dual-compound protocol combining semaglutide and tirzepatide—starting at $289/mo. This option suits individuals with severe obesity, significant insulin resistance, or prior inadequate response to single-agent therapy. All medications come from licensed 503A compounding pharmacies and are available in all 50 states without insurance or membership requirements, with HSA/FSA eligibility included.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What percentage of people lose weight on tirzepatide?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
How much weight can I realistically lose with tirzepatide?
Most patients lose between 15% and 22% of body weight over 12 months of tirzepatide treatment. Weight loss typically accelerates between months 2 and 6, then stabilizes. Results depend on consistent medication use, dietary adherence, physical activity, and your individual genetic and metabolic profile.
How is PlexusDx tirzepatide different from brand-name Mounjaro?
PlexusDx tirzepatide is compounded by licensed 503A pharmacies to identical pharmaceutical standards as brand-name Mounjaro, but costs significantly less—starting at just $249/mo with no insurance required. PlexusDx also offers genetic testing and personalized dosing optimization not typically available through brand medications.
Are there side effects that reduce tirzepatide success rates?
Common tirzepatide side effects include nausea, vomiting, and constipation, which typically diminish within 2-4 weeks as your body adjusts. Serious side effects are rare but include pancreatitis and severe allergic reactions. Discontinuation due to side effects occurs in fewer than 5% of users, and PlexusDx providers adjust dosing or offer alternative compounds if tolerance becomes problematic.
How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?
No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Inject Mounjaro into Your Thigh: A Comprehensive Guide
Navigating Your Nutrition: How Many Calories a Day Should You Eat on Mounjaro?